We are studying whether crizotinib can help reduce tumor size in children with severe type 2 neurofibromatosis who are not eligible for surgery or radiotherapy. We will also evaluate the safety of this treatment.
Health conditions and diseases that the clinical trial is designed to study and treat.
Neurofibromatosis Type 2 (NF2) is a genetic disorder that causes the growth of noncancerous tumors on the nerves, particularly affecting hearing and balance. It often leads to complications such as hearing loss and other neurological issues, especially in children.
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.